SironRX Therapeutics

SironRX Therapeutics was developing novel therapies to promote dermal wound repair and reduce scarring. The company’s therapeutic platform was based on the delivery of Stromal cell-Derived Factor 1 (SDF-1), which has been shown to promote tissue repair by¬†recruiting¬†stem cells to the damaged organ. SDF-1 has also been shown to prevent cell death and promote new blood vessel formation.

Additional Investors:
Cleveland Clinic, Early Stage Partners, Fletcher Spaght Ventures, JumpStart Inc., Ohio TechAngels, Rev1 Ventures, Second Generation


Fund II